The Place of Chemotherapy in The Evolving Treatment Landscape for Patients With HR-positive/HER2-negative MBC-Reference-Cited by-同舟云学术

The Place of Chemotherapy in The Evolving Treatment Landscape for Patients With HR-positive/HER2-negative MBC

Published:2021-10 Issue: Volume: Page:
ISSN:1526-8209
Container-title:Clinical Breast Cancer
language:en
Short-container-title:Clinical Breast Cancer

Author:

Twelves Chris,Bartsch Rupert,Ben-Baruch Noa Efrat,Borstnar Simona^ORCID,Dirix Luc,Tesarova Petra,Timcheva Constanta^ORCID,Zhukova Lyudmila,Pivot Xavier

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference133 articles.

1. Cancer mortality in Europe, 2005-2009, and an overview of trends since 1980;Bosetti;Ann Oncol,2013

2. Trends and predictions to 2020 in breast cancer mortality in Europe;Carioli;Breast,2017

3. Hormone receptor-positive, HER2-negative metastatic breast cancer: redrawing the lines;Matutino;Curr Oncol,2018

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real-world treatment patterns and outcomes in patients with HR+/HER2− metastatic breast cancer treated with chemotherapy in the United States;ESMO Open;2024-09

2. Sacituzumab govitecan for metastatic breast cancer: the TROPiCS-02 trial – Authors' reply;The Lancet;2024-07

4. Neoadjuvant nivolumab + palbociclib + anastrozole for oestrogen receptor-positive/human epidermal growth factor receptor 2-negative primary breast cancer: Results from CheckMate 7A8;The Breast;2023-12

5. Paclitaxel plus Eftilagimod Alpha, a Soluble LAG-3 Protein, in Metastatic, HR+ Breast Cancer: Results from AIPAC, a Randomized, Placebo Controlled Phase IIb Trial;Clinical Cancer Research;2023-11-08